Overexpression of SMYD2 contributes to malignant outcome in gastric cancer-Reference-Cited by-同舟云学术

Overexpression of SMYD2 contributes to malignant outcome in gastric cancer

Published:2014-10-16 Issue:2 Volume:112 Page:357-364
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Komatsu S,Ichikawa D,Hirajima S,Nagata H,Nishimura Y,Kawaguchi T,Miyamae M,Okajima W,Ohashi T,Konishi H,Shiozaki A,Fujiwara H,Okamoto K,Tsuda H,Imoto I,Inazawa J,Otsuji E

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2014543.pdf

Reference45 articles.

1. Abu-Farha M, Lambert JP, Al-Madhoun AS, Elisma F, Skerjanc IS, Figeys D (2008) The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol Cell Proteomics 7: 560–572.

2. Abu-Farha M, Lanouette S, Elisma F, Tremblay V, Butson J, Figeys D, Couture JF (2011) Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2. J Mol Cell Biol 3: 301–308.

3. Anglin JL, Song Y (2013) A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L. J Med Chem 56: 8972–8983.

4. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687–697.

5. Barros Filho MC, Katayama ML, Brentani H, Abreu AP, Barbosa EM, Oliveira CT, Góes JC, Brentani MM, Folgueira MA (2010) Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancer patients. Braz J Med Biol Res 43: 1225–1231.

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of SMYD2 attenuates paraquat-induced pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition through the GLIPR2/ERK/p38 axis;Pesticide Biochemistry and Physiology;2024-06

2. Epigenetic upregulation of MNAT1 by SMYD2 is linked to PI3K/AKT activation and tumorigenesis of pancreatic adenocarcinoma;HISTOL HISTOPATHOL;2024

3. Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide;Oncogene;2024-01-19

4. CircSP3 promotes ccRCC progression and sunitinib resistance via encoding SP3- 461aa to stabilize MYH9 and activate the PI3K-AKT pathway;2023-12-07

5. Neutrophil extracellular traps promote gastric cancer cell metastasis via the NAT10-mediated N4-acetylcytidine modification of SMYD2;Cellular Signalling;2023-12